AELIX-002

AELIX-002 is a therapeutic HIV vaccine regimen developed by Aelix Therapeutics. It is based on the HTI (HIVACAT T-cell immunogen), a synthetic antigen designed to elicit T-cell immune responses against highly conserved regions of the HIV-1 genome. These regions are associated with natural viral control in individuals who maintain low viral loads without medication (elite controllers). The vaccine is administered using a heterologous prime-boost strategy involving three distinct delivery platforms: a DNA plasmid vector (DNA.HTI), a Modified Vaccinia Ankara viral vector (MVA.HTI), and a Chimpanzee Adenovirus vector (ChAdOx1.HTI). The regimen is intended to enable people living with HIV to maintain viral suppression during analytical treatment interruption (ATI) from antiretroviral therapy.

Other names

HTI vaccineHTI immunogen vaccineHIVACAT T-cell immunogen vaccine